MIcrovascular dysfuNction In Moderate-severe Psoriasis
NCT04271540
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Psoriasis
Cardiovascular Disease
Interventions
DRUG:
Tildrakizumab
Sponsor
Marcelo F. Di Carli, MD, FACC